Portal de Periódicos da CAPES

Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916

2007; Lippincott Williams & Wilkins; Volume: 178; Issue: 5 Linguagem: Inglês

10.1016/j.juro.2007.07.026

1527-3792

Bruce Montgomery, Bryan Goldman, Catherine M. Tangen, Maha Hussain, Daniel P. Petrylak, Stephanie T. Page, Eric A. Klein, E. David Crawford,

Cancer Risks and Factors

No AccessJournal of UrologyAdult urology1 Nov 2007Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916is accompanied byObesity and Prostate Cancer: Importance of Race and Stage of Disease R. Bruce Montgomery, Bryan Goldman, Catherine M. Tangen, Maha Hussain, Daniel P. Petrylak, Stephanie Page, Eric A. Klein, and E. David Crawford R. Bruce MontgomeryR. Bruce Montgomery , Bryan GoldmanBryan Goldman , Catherine M. TangenCatherine M. Tangen , Maha HussainMaha Hussain , Daniel P. PetrylakDaniel P. Petrylak , Stephanie PageStephanie Page , Eric A. KleinEric A. Klein , and E. David CrawfordE. David Crawford View All Author Informationhttps://doi.org/10.1016/j.juro.2007.07.026AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer. Materials and Methods: We examined the prognostic impact of body mass index in patient cohorts from phase III randomized studies coordinated by the Southwest Oncology Group. The first study included 1,006 men treated with androgen deprivation for metastatic prostate cancer. The second study included 671 patients treated with chemotherapy for metastatic, androgen independent prostate cancer. Results: Among men with androgen dependent disease, higher body mass index was associated with longer overall (p <0.001) and progression-free (p = 0.009) survival, as well as with an increased likelihood of achieving a prostate specific antigen nadir less than 4 ng/ml (p = 0.008). In multivariate analysis adjusting for risk factors, increasing body mass index was positively correlated with overall survival (p <0.01) and overweight but not obese patients (body mass index 27 to 29.9) had a significantly improved outcome compared to normal weight patients, with hazard ratios for risk of progression and death of 0.82 (95% CI 0.69, 0.98) and 0.75 (95% CI 0.63, 0.89), respectively. Among men with androgen independent prostate cancer, no clear association could be detected between body mass index and progression-free survival, overall survival or prostate specific antigen response. Conclusions: This study revealed higher body mass index to be associated with better overall and progression-free survival in patients with androgen dependent metastatic prostate cancer. Among men who had androgen independent disease, no significant association was found between body mass index and survival. References 1 : Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA2004; 291: 2847. Google Scholar 2 : Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev2001; 10: 345. Google Scholar 3 : Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med1992; 116: 26. Google Scholar 4 : Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol2004; 22: 446. Google Scholar 5 : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med2003; 348: 1625. Google Scholar 6 : Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol2005; 23: 2434. Google Scholar 7 : Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology2002; 60: 120. Google Scholar 8 : Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med1998; 339: 1036. Crossref, Medline, Google Scholar 9 : SWOG 99-16: randomized phase III trial of docetaxel/estramustine versus mitoxantrone/prednisone in men with androgen-independent prostate cancer. J Clin Oncol2004; 22: 3. Google Scholar 10 Physical status: the use and interpretation of anthropometry: Report of a WHO Expert Committee. World Health Organ Tech Rep Ser1995; 854: 1. Google Scholar 11 : Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am J Clin Oncol2002; 25: 1. Google Scholar 12 : Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer2007; 109: 675. Google Scholar 13 : Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev2006; 15: 1977. Google Scholar 14 : Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res2005; 11: 6889. Google Scholar 15 : Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso Study. J Clin Endocrinol Metab2004; 89: 6039. Google Scholar 16 : Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism1995; 44: 513. Google Scholar 17 : Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab2006; 290: E856. Google Scholar 18 : Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res2007; 13: 241. Google Scholar 19 : The androgen axis in recurrent prostate cancer. Clin Cancer Res2004; 10: 440. Google Scholar 20 : Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer. J Clin Oncol2006; 24: 4554. Google Scholar University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Columbia University, New York, New York, Clinic Foundation, Cleveland, Ohio, and University of Colorado, Denver, Colorado© 2007 by American Urological AssociationFiguresReferencesRelatedDetailsCited byXu M, Huelster H, Hatcher J, Avulova S, Stocks B, Glaser Z, Moses K and Silver H (2020) Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate CancerJournal of Urology, VOL. 205, NO. 3, (800-805), Online publication date: 1-Mar-2021.Siddiqui S (2009) Obesity and Prostate Cancer: An Insight Into Postmodern MedicineJournal of Urology, VOL. 182, NO. 1, (14-15), Online publication date: 1-Jul-2009. (2018) Reply by AuthorJournal of Urology, VOL. 179, NO. 6, (2482-2482), Online publication date: 1-Jun-2008.Related articlesJournal of Urology14 Sep 2007Obesity and Prostate Cancer: Importance of Race and Stage of Disease Volume 178Issue 5November 2007Page: 1946-1951 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsobesitybody mass indexhormone antagonistsprostatic neoplasmsMetrics Author Information R. Bruce Montgomery Financial interest and/or other relationship with Dendreon and Sanofi-Aventis. More articles by this author Bryan Goldman Financial interest and/or other relationship with Dendreon and Sanofi-Aventis. More articles by this author Catherine M. Tangen Nothing to disclose. More articles by this author Maha Hussain Financial interest and/or other relationship with Dendreon and Sanofi-Aventis. More articles by this author Daniel P. Petrylak Financial interest and/or other relationship with GPC Biotech, Cell Genesys, Aventis, Eli Lilly and Celgene. More articles by this author Stephanie Page Financial interest and/or other relationship with Dendreon and Sanofi-Aventis. More articles by this author Eric A. Klein Financial interest and/or other relationship with Dendreon and Sanofi-Aventis. More articles by this author E. David Crawford Financial interest and/or other relationship with Merck, Sanofi-Aventis Group, Auxilium, Oncura, Endocare, National Institutes of Health and University of Colorado Cancer Center. More articles by this author Expand All Advertisement PDF downloadLoading ...